BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Borsa Italiana 09:29:51 2024-06-21 am EDT | ||
| 29.9 EUR | -0.23% |
|
| Current month | +26.40% | ||
| 1 month | +45.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 29.9 | -0.23% |
| 24-06-20 | 29.97 | -2.44% |
| 24-06-19 | 30.72 | +0.99% |
| 24-06-18 | 30.42 | +1.37% |
| 24-06-17 | 30.01 | +2.32% |
Real-time Borsa Italiana
Last update June 21, 2024 at 09:29 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| S33513 | |
| ISIN | DE000SU6N914 |
| Date issued | 2024-01-09 |
| Strike | 568.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.62 € |
|---|---|
| Lowest since issue | 6.52 € |
| Spread | 0.4 € |
| Spread % | 1.33% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Certificates
- S33513 Certificat
